Base de dados : MEDLINE
Pesquisa : D26.776.708.645 [Categoria DeCS]
Referências encontradas : 12450 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1245 ir para página                         

  1 / 12450 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471102
[Au] Autor:Yoo SG; Cho MJ; Kim US; Baek SH
[Ad] Endereço:Department of Ophthalmology, Kim's Eye Hospital, Seoul, Korea.
[Ti] Título:Cycloplegic Refraction in Hyperopic Children: Effectiveness of a 0.5% Tropicamide and 0.5% Phenylephrine Addition to 1% Cyclopentolate Regimen.
[So] Source:Korean J Ophthalmol;31(3):249-256, 2017 Jun.
[Is] ISSN:2092-9382
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the effectiveness of a cycloplegic regimen using 0.5% tropicamide and 0.5% phenylephrine (Tropherine, Hanmi Pharm), in addition to 1% cyclopentolate, in hyperopic children. METHODS: The medical records of hyperopic patients below the age of 14 years who had undergone cycloplegic retinoscopy were retrospectively reviewed. Cycloplegic refractions were performed using one of two cycloplegic regimens. Regimen 1 was a Tropherine-added regimen comprising the administration of one drop of 1% cyclopentolate followed by two to three drops of Tropherine added at 15-minute intervals. Regimen 2 was a cyclopentolate-only regimen comprising the administration of three to four drops of 1% cyclopentolate at 15-minute intervals. The mean difference between noncycloplegic and cycloplegic refraction was compared between the two regimens. RESULTS: A total of 308 eyes of 308 hyperopic children were included. The mean difference (±standard deviation) in the spherical equivalent (SE) between cycloplegic and noncycloplegic refraction was significantly larger in regimen 2 than in regimen 1, with values of +1.70 ± 1.03 diopters (D) and +1.25 ± 0.89 D, respectively (p=0.001). The SE change after cycloplegia was significantly different between the two regimens only in patients aged 5 years or younger (p=0.001), particularly in those with high hyperopia with an SE ≥5 D (p=0.005) or fully accommodative esotropia (p=0.009). There was no significant difference between the two regimens in patients older than 5 years, regardless of the presence of high hyperopia or fully accommodative esotropia. CONCLUSIONS: The Tropherine-added regimen exerted a weaker cycloplegic effect than the cyclopentolate-only regimen, particularly in children under the age of 5 years with high hyperopia or fully accommodative esotropia. However, the difference in refraction between the two regimens was small. A Tropherine-added regimen can be effective in hyperopic children, with less associated discomfort than the instillation of cyclopentolate.
[Mh] Termos MeSH primário: Acomodação Ocular/efeitos dos fármacos
Ciclopentolato/administração & dosagem
Oftalmopatias Hereditárias/tratamento farmacológico
Hiperopia/tratamento farmacológico
Fenilefrina/administração & dosagem
Refração Ocular/efeitos dos fármacos
Tropicamida/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Quimioterapia Combinada
Oftalmopatias Hereditárias/fisiopatologia
Feminino
Seguimentos
Seres Humanos
Hiperopia/fisiopatologia
Lactente
Recém-Nascido
Masculino
Midriáticos/administração & dosagem
Soluções Oftálmicas/administração & dosagem
Estudos Retrospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mydriatics); 0 (Ophthalmic Solutions); 1WS297W6MV (Phenylephrine); I76F4SHP7J (Cyclopentolate); N0A3Z5XTC6 (Tropicamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.3341/kjo.2016.0007


  2 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390284
[Au] Autor:He Y; Li J; Zhu J; Jie Y; Wang N; Wang J
[Ad] Endereço:Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory.
[Ti] Título:The improvement of dry eye after cataract surgery by intraoperative using ophthalmic viscosurgical devices on the surface of cornea: The results of a consort-compliant randomized controlled trial.
[So] Source:Medicine (Baltimore);96(50):e8940, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUD: This study aimed to investigate the protective effect of intraoperative used hydroxypropyl methylcellulose (HPMC 2%) on the ocular surface after cataract surgery. METHODS: A total of 149 eyes (149 patients) diagnosed with age-related cataract, age 69.19 ±â€Š9.74 years, were enrolled in this prospective, parallel-design, continuous, randomised controlled study. Patients were randomly assigned to receive HPMC 2% (study group) or balanced salt solution (control group) during the surgery to moisturize the cornea surface. The Ocular Surface Disease Index, Schirmer test without topical anesthetics, tear break-up time, and corneal fluorescein staining were assessed preoperatively, 1 day, 1 week, and 1 month after the surgery, respectively. RESULTS: The Schirmer test value of male patients in the study group at 1 week postoperation was higher than that of male patients in the control group (P = .019). For patients diagnosed with dry eye before the surgery, Schirmer test value in the male patients in the study group at 1 month after surgery was higher than that in the male patients in the control group (P = .037). Furthermore, for the cluster of preoperative dry eye patients whose surgical time was longer than median, corneal fluorescein staining of the patients in the study group was superior to that of the patients in the control group (P = .032). CONCLUSION: Intraoperative use of HPMC 2% on the cornea surface could improve clinical outcomes of tear film and ocular surface health to some degree, especially in the patients diagnosed with dry eye before the surgery, male patients, and patients whose surgical time was relatively longer.
[Mh] Termos MeSH primário: Extração de Catarata/métodos
Síndromes do Olho Seco/prevenção & controle
Derivados da Hipromelose/uso terapêutico
Soluções Oftálmicas/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Córnea
Síndromes do Olho Seco/etiologia
Feminino
Seres Humanos
Cuidados Intraoperatórios
Masculino
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Ophthalmic Solutions); 3NXW29V3WO (Hypromellose Derivatives)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008940


  3 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311455
[Au] Autor:Nakagawa H; Matsumaru Y; Nose S; Sasaki H; Kitahara T
[Ad] Endereço:Department of Pharmacy, Nagasaki University Hospital.
[Ti] Título:[Evaluation of the Safety of 2.0% Ganciclovir Eye Drops for Hospital Preparation].
[So] Source:Yakugaku Zasshi;138(1):107-110, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:The concentration of ganciclovir eye drops for hospital preparation was changed from 0.5% to 2.0% at the Nagasaki University Hospital from March 2015. We investigated the incidence of side effects in 12 patients using 2.0% ganciclovir eye drops and evaluated the cytotoxicity of 2.0% ganciclovir eye drops using cultured rabbit corneal cells in vitro. As a side effect of 2.0% ganciclovir eye drops, three patients exhibited an early feeling of transient stimulation. The 2.0% ganciclovir eye drops did not demonstrate cell cytotoxicity for cultured corneal cells after 5 min, but did after 10 min. These findings suggested that the 2.0% ganciclovir eye drops can be used without corneal epithelium disorder in clinical settings.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Ganciclovir/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Córnea/citologia
Córnea/efeitos dos fármacos
Testes Imunológicos de Citotoxicidade
Relação Dose-Resposta a Droga
Ganciclovir/toxicidade
Hospitais Universitários
Seres Humanos
Incidência
Japão/epidemiologia
Soluções Oftálmicas
Coelhos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ophthalmic Solutions); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00015


  4 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422755
[Au] Autor:Maharana PK; Raghuwanshi S; Chauhan AK; Rai VG; Pattebahadur R
[Ad] Endereço:Department of Ophthalmology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
[Ti] Título:Comparison of the Efficacy of Carboxymethylcellulose 0.5%, Hydroxypropyl-guar Containing Polyethylene Glycol 400/Propylene Glycol, and Hydroxypropyl Methyl Cellulose 0.3% Tear Substitutes in Improving Ocular Surface Disease Index in Cases of Dry Eye.
[So] Source:Middle East Afr J Ophthalmol;24(4):202-206, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare the efficacy of carboxymethylcellulose 0.5% (CMC), hydroxypropyl-guar containing polyethylene glycol 400/propylene glycol (PEG/PG), and hydroxypropyl methylcellulose 0.3% (HPMC) as tear substitutes in patients with dry eye. METHODS: A retrospective evaluation of cases presenting with symptoms of dry eye from July 2014 to June 2015 was done. Patients with Ocular Surface Disease Index (OSDI) scoring >12 were included in the study. Parameters such as age, gender, Schirmer test (ST), and tear film breakup time (TBUT) were recorded on day 0, week 1, and week 4. For analysis, cases were divided into three groups; Group 1 - CMC, Group 2 - PEG/PG, and Group 3 - HPMC. RESULTS: Overall, 120 patients were included in the study. Demographic data and baseline characteristics were comparable among the groups. Group 2 had significant improvement in percentage change in OSDI (weeks 0-1, 0-4, and 1-4, = 0.00), TBUT (weeks 0-1, = 0.01; 0-4, = 0.006; and 1-4, = 0.007), and in ST (weeks 0-1, = 0.02; 0-4, = 0.002; and 1-4, = 0.008) compared to Group 1 at all follow-ups. Group 3 had improvements similar to Group 2, but it was not at all follow-ups (improvement in percentage change OSDI [weeks 0-1, 0-4, and 1-4, = 0.00], TBUT [weeks 0-1, = 0.10; 0-4, = 0.03; and 1-4, = 0.04], and in ST [weeks 0-1, = 0.007; 0-4, = 0.03; and 1-4, = 0.12]). No significant difference was found between Groups 2 and 3. CONCLUSIONS: Hydroxypropyl-guar containing PEG/PG and HPMC as tear substitutes are better than CMC. While HPMC was comparable to PEG/PG in subjective improvement, the objective improvement was not consistent.
[Mh] Termos MeSH primário: Carboximetilcelulose Sódica/administração & dosagem
Síndromes do Olho Seco/tratamento farmacológico
Derivados da Hipromelose/administração & dosagem
Lubrificantes Oftálmicos/administração & dosagem
Polissacarídeos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Adulto
Combinação de Medicamentos
Síndromes do Olho Seco/fisiopatologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Soluções Oftálmicas
Polietilenoglicóis/química
Polissacarídeos/química
Propilenoglicol/química
Estudos Retrospectivos
Lágrimas/fisiologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Lubricant Eye Drops); 0 (Ophthalmic Solutions); 0 (Polysaccharides); 0 (hydroxypropyl guar); 30IQX730WE (Polyethylene Glycols); 3NXW29V3WO (Hypromellose Derivatives); 6DC9Q167V3 (Propylene Glycol); B697894SGQ (polyethylene glycol 400); K679OBS311 (Carboxymethylcellulose Sodium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_165_15


  5 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452989
[Au] Autor:Labetoulle M; Chiambaretta F; Shirlaw A; Leaback R; Baudouin C
[Ad] Endereço:Service d'Ophtalmologie, CHU Bicêtre, APHP, Université Paris Sud, Paris, France.
[Ti] Título:Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye.
[So] Source:Eye (Lond);31(10):1409-1416, 2017 Oct.
[Is] ISSN:1476-5454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PurposeTo assess the safety and efficacy of an eye drop combining osmoprotectants, carboxymethylcellulose and hyaluronic acid (O/CMC/HA) in reducing symptomatic, moderate to severe dry eye, compared with HA.MethodsIn this investigator-masked, randomised study, patients instilled 1-2 drops/eye of O/CMC/HA or HA (2-6 times/day) for 3 months. Primary endpoint: mean change in Global Ocular Staining Score (GOSS) from baseline at day 35. Noninferiority of O/CMC/HA was tested in the per-protocol population; if achieved, superiority was tested in the intent-to-treat population. Secondary efficacy endpoints: mean change from baseline in GOSS, Ocular Surface Disease Index (OSDI), Schirmer score, tear break-up time (TBUT), corneal/conjunctival staining, conjunctival hyperaemia, symptoms, and patient/investigator assessments.ResultsBaseline characteristics were comparable between groups (n=40 each). O/CMC/HA was noninferior (and not superior) to HA based on similar GOSS reductions from baseline at day 35 and month 3 in both groups (P=0.778, day 35, per-protocol population). Overall, O/CMC/HA and HA provided similar reductions in OSDI, Schirmer score, TBUT, corneal staining and hyperaemia from baseline at 35 days (P≥0.155). More patients reported less severe stinging/burning, sandiness/grittiness, and painful/sore eyes at month 3 with O/CMC/HA (P≤0.039), and more rated the dropper bottle easy to use (87.5%), compared with HA (46.2%; P=0.002). Other patient and investigator assessments were similar between groups. O/CMC/HA and HA were well tolerated.ConclusionsO/CMC/HA is noninferior to HA in improving objective signs of dry eye, with potential advantages for subjective symptoms and patient acceptance.
[Mh] Termos MeSH primário: Carboximetilcelulose Sódica/administração & dosagem
Síndromes do Olho Seco/tratamento farmacológico
Ácido Hialurônico/administração & dosagem
Lágrimas/química
[Mh] Termos MeSH secundário: Carboximetilcelulose Sódica/farmacocinética
Relação Dose-Resposta a Droga
Esquema de Medicação
Síndromes do Olho Seco/diagnóstico
Feminino
Seres Humanos
Ácido Hialurônico/farmacocinética
Masculino
Meia-Idade
Soluções Oftálmicas/administração & dosagem
Osmose/efeitos dos fármacos
Índice de Gravidade de Doença
Resultado do Tratamento
Viscossuplementos/administração & dosagem
Viscossuplementos/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Ophthalmic Solutions); 0 (Viscosupplements); 9004-61-9 (Hyaluronic Acid); K679OBS311 (Carboxymethylcellulose Sodium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1038/eye.2017.73


  6 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390490
[Au] Autor:Zhu Y; Sun C; Zhang X; Shentu X
[Ad] Endereço:Eye Center, 2nd Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, Zhejiang, China.
[Ti] Título:Ptosis induced by topical steroid eye drops: Two cases reports.
[So] Source:Medicine (Baltimore);96(51):e9288, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Ptosis is a rare complication of periocular steroid use. Studies report that local injections of steroids produce ptosis. We describe the first 2 cases of ptosis because of long-term treatment with topical steroid eye drops. PATIENT CONCERNS: Two cases admitted to our hospital because of ptosis of their right eye after long-term treatment with topical steroid eye drops. Both of them had uncontrolled Posner-Schlossman syndrome. DIAGNOSIS: Two cases were diagnosed as steroid-related ptosis. INTERVENTIONS: Regulatory anti-inflammation therapy was prescribed for case 1, and after inflammation control, phacoemulsification was done for her. Six months after steroid withdrawal, the levator resection of the right eye was performed. Case 2 refused our advice of steroid reduction and ptosis surgery. OUTCOMES: After surgery, case 1 retained a symmetrical appearance during a 1-year follow-up. In the surgery, we found thin levator muscles and slack levator palpebrae superioris aponeurosis (LPSA) in the affected eye. Postoperative transmission electron microscopy revealed typical signs of apoptosis in levator muscle cells. LESSONS: We suggest topical application of steroids induces levator muscle apoptosis and LPSA weakness, and results in ptosis.
[Mh] Termos MeSH primário: Corticosteroides/efeitos adversos
Blefaroptose/induzido quimicamente
Extração de Catarata/métodos
Músculos Oculomotores/efeitos dos fármacos
Soluções Oftálmicas/efeitos adversos
Facoemulsificação/métodos
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Adulto
Blefaroplastia/métodos
Blefaroptose/cirurgia
Catarata/diagnóstico
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Cuidados Pós-Operatórios
Medição de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Ophthalmic Solutions)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009288


  7 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458352
[Au] Autor:Matsuda T; Hiraoka S; Urashima H; Ogura A; Ishida T
[Ad] Endereço:Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University.
[Ti] Título:Preparation of an Ultrafine Rebamipide Ophthalmic Suspension with High Transparency.
[So] Source:Biol Pharm Bull;40(5):665-674, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A 2% commercially available, milky-white, rebamipide micro-particle suspension is used to treat dry eyes, and it causes short-term blurring of the patient's vision. In the current study, to improve the transparency of a rebamipide suspension, we attempted to obtain a clear rebamipide suspension by transforming the rebamipide particles to an ultrafine state. In the initial few efforts, various rebamipide suspensions were prepared using a neutralizing crystallization method with additives, but the suspensions retained their opaque quality. However, as a consequence of several critical improvements in the neutralizing crystallization methods such as selection of additives for crystallization, process parameters during crystallization, the dispersion method, and dialysis, we obtained an ultrafine rebamipide suspension (2%) that was highly transparent (transmittance at 640 nm: 59%). The particle size and transparency demonstrated the fewest level of changes at 25°C after 3 years, compared to initial levels. During that period, no obvious particle sedimentation was observed. The administration of this ultrafine rebamipide suspension (2%) increased the conjunctival mucin, which was comparable to the commercially available micro-particle suspension (2%). The corneal and conjunctival concentration of rebamipide following ocular administration of the ultrafine suspension was slightly higher than that of the micro-particle suspension. The ultrafine rebamipide suspension (eye-drop formulation) with a highly transparent ophthalmic clearness should improve a patient's QOL by preventing even a shortened period of blurred vision.
[Mh] Termos MeSH primário: Alanina/análogos & derivados
Antiulcerosos/administração & dosagem
Antiulcerosos/química
Soluções Oftálmicas/química
Quinolonas/administração & dosagem
Quinolonas/química
[Mh] Termos MeSH secundário: Administração Oftálmica
Alanina/administração & dosagem
Alanina/química
Animais
Túnica Conjuntiva/efeitos dos fármacos
Túnica Conjuntiva/metabolismo
Córnea/efeitos dos fármacos
Córnea/metabolismo
Cristalização
Diálise
Masculino
Mucinas/metabolismo
Tamanho da Partícula
Coelhos
Suspensões
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Mucins); 0 (Ophthalmic Solutions); 0 (Quinolones); 0 (Suspensions); LR583V32ZR (rebamipide); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00962


  8 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27775976
[Au] Autor:Grey KR; Warshaw EM
[Ad] Endereço:From the *University of Minnesota Medical School; †HCMC Parkside Occupational and Contact Dermatitis Clinic; ‡Department of Dermatology, Minneapolis Veterans Affairs Medical Center; and §Department of Dermatology, University of Minnesota Medical School, Minneapolis.
[Ti] Título:Allergic Contact Dermatitis to Ophthalmic Medications: Relevant Allergens and Alternative Testing Methods.
[So] Source:Dermatitis;27(6):333-347, 2016 Nov/Dec.
[Is] ISSN:2162-5220
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Allergic contact dermatitis is an important cause of periorbital dermatitis. Topical ophthalmic agents are relevant sensitizers. Contact dermatitis to ophthalmic medications can be challenging to diagnose and manage given the numerous possible offending agents, including both active and inactive ingredients. Furthermore, a substantial body of literature reports false-negative patch test results to ophthalmic agents. Subsequently, numerous alternative testing methods have been described. This review outlines the periorbital manifestations, causative agents, and alternative testing methods of allergic contact dermatitis to ophthalmic medications.
[Mh] Termos MeSH primário: Dermatite Alérgica de Contato/etiologia
Dermatoses Faciais/etiologia
Lubrificantes Oftálmicos/efeitos adversos
Soluções Oftálmicas/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oftálmica
Agonistas de Receptores Adrenérgicos alfa 1/efeitos adversos
Antagonistas Adrenérgicos beta/efeitos adversos
Antibacterianos/efeitos adversos
Anti-Infecciosos Locais/efeitos adversos
Anti-Inflamatórios/efeitos adversos
Antineoplásicos/efeitos adversos
Antivirais/efeitos adversos
Inibidores da Anidrase Carbônica/efeitos adversos
Antagonistas Colinérgicos/efeitos adversos
Glaucoma/tratamento farmacológico
Antagonistas dos Receptores Histamínicos/efeitos adversos
Seres Humanos
Agonistas Muscarínicos/efeitos adversos
Antagonistas Muscarínicos/efeitos adversos
Prostaglandinas Sintéticas/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Agonists); 0 (Adrenergic beta-Antagonists); 0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); 0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents); 0 (Antiviral Agents); 0 (Carbonic Anhydrase Inhibitors); 0 (Cholinergic Antagonists); 0 (Histamine Antagonists); 0 (Lubricant Eye Drops); 0 (Muscarinic Agonists); 0 (Muscarinic Antagonists); 0 (Ophthalmic Solutions); 0 (Prostaglandins, Synthetic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  9 / 12450 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742619
[Au] Autor:Wang AL; Weinlander E; Metcalf BM; Barney NP; Gamm DM; Nehls SM; Struck MC
[Ad] Endereço:*Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI; †McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI; and ‡Waisman Center, University of Wisconsin-Madison, Madison WI.
[Ti] Título:Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers.
[So] Source:Cornea;36(11):1426-1428, 2017 Nov.
[Is] ISSN:1536-4798
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report the clinical course of 6 patients with refractory neurotrophic corneal ulcers that were treated with topical insulin drops. METHODS: Retrospective chart review of patients who had neurotrophic corneal ulcers or epithelial defects refractory to standard medical and surgical treatment. Insulin drops, prepared by mixing regular insulin in artificial tears with a polyethylene glycol and propylene glycol base at a concentration of 1 unit per milliliter, were prescribed 2 to 3 times daily. RESULTS: Six patients, aged 2 to 73 years, developed neurotrophic corneal ulcers refractory to a range of medical and surgical treatments, including bandage contact lens, amniotic membrane grafting, and permanent tarsorrhaphy. Each patient was administered topical insulin drops with complete corneal reepithelialization within 7 to 25 days. CONCLUSIONS: Topical insulin may be a simple and effective treatment for refractory neurotrophic corneal ulcers. Further study is required to determine the clinical efficacy and side effect profile of insulin drops.
[Mh] Termos MeSH primário: Úlcera da Córnea/tratamento farmacológico
Hipoglicemiantes/administração & dosagem
Insulina/administração & dosagem
Doenças do Nervo Trigêmeo/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Pré-Escolar
Feminino
Seres Humanos
Masculino
Meia-Idade
Soluções Oftálmicas
Reepitelização
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Insulin); 0 (Ophthalmic Solutions)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1097/ICO.0000000000001297


  10 / 12450 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381940
[Au] Autor:Moraes BRM; Nascimento MVDD; Neto EDDS; Santo RM
[Ti] Título:Topical steroids eye drops in conjunctival reactive lymphoid hyperplasia: Case report.
[So] Source:Medicine (Baltimore);96(47):e8656, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Conjunctival lymphoproliferative lesions constitute a significant diagnostic challenge and it is essential to exclude neoplastic lesions. Histopathological and immunohistochemical tests are very useful in establishing the correct diagnosis. Reactive lymphoid hyperplasia (RLH) is part of a spectrum of lymphocytic infiltrative disorders. Evidence is scarce regarding appropriate treatment of conjunctival RLH. We report a case treated with topical corticosteroid. PATIENT CONCERNS: A 40 year-old female presented with a 7-month history of a slow growth tumor in the superior conjunctiva of the right eye. Slit-lamp examination demonstrated salmon colored lesion in the upper conjunctiva, with little conjunctival injection, but no significant neovascularization. There was no eyelid involvement. DIAGNOSES: Ultrasound biomicroscopy showed lesion depth (1.53 mm) and larger diameter (10.73 mm). Pathological examination revealed a chronic inflammatory process with conjunctival folicular hyperplasia. The immunohistochemistry examination showed predominance of CD20, CD23, and CD 3 e CD 5. INTERVENTION: We started topic prednisolone 1% 6 times daily. OUTCOMES: Six months after starting treatment, the lesion completely resolved, without any side-effects or recurrence during three-year follow-up period. LESSONS: Conjunctival RLH can be managed in various ways, depending on patient symptonm, comorbities, and disease distribution. Surgical resection with cryotherapy, radiotherapy, systemic corticosteroids, subconjunctival triamcinolone, and rituximab are some options. There is no strong evidence in the literature of conjunctival RLH successfully treated with topical eye drops corticosteroid. In this report, we obtained completely resolution of conjunctival RLH with topical corticosteroid. CONCLUSION: Topical eye drops corticosteroids are an alternative treatment for selected cases of conjuncitval RLH with no orbital or eyelid involvement.
[Mh] Termos MeSH primário: Túnica Conjuntiva/patologia
Neoplasias da Túnica Conjuntiva/diagnóstico
Prednisolona/administração & dosagem
Pseudolinfoma
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Diagnóstico Diferencial
Feminino
Glucocorticoides/administração & dosagem
Seres Humanos
Imuno-Histoquímica
Microscopia Acústica/métodos
Soluções Oftálmicas
Pseudolinfoma/diagnóstico
Pseudolinfoma/tratamento farmacológico
Pseudolinfoma/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ophthalmic Solutions); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008656



página 1 de 1245 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde